The Editors’ views: European Pharmaceutical Review’s 2020 round-up
Junior Editors of European Pharmaceutical Review, Hannah Balfour and Victoria Rees, discuss some of the most noteworthy news and announcements from this year.
List view / Grid view
Junior Editors of European Pharmaceutical Review, Hannah Balfour and Victoria Rees, discuss some of the most noteworthy news and announcements from this year.
Osteoporosis treatments including denosumab, zoledronate and calcium could protect patients against COVID-19, researchers have said.
Once patents expire for biologic medicines, a market opportunity opens up for biosimilars, a cheaper alternative. With more patents due to expire soon, what will the future look like for biologic medicines?
2019 has seen a marked increase of antibody biosimilar product approvals in the first half of the year, according to a report.
An integrated Phase I/III trial has enrolled its first patient to test a biosimilar for denosumab to treat postmenopausal osteoporosis.
The drug denosumab was superior to a commonly used drug in a 12-month study enrolling 795 patients...